The calcitonin gene-related peptide (CGRP) is a 37-residue peptide with pronounced physiological activities, making it an interesting lead for drug development In our previous work, we designed constrained analogues of the peptide. The biological activities of these proved that the disulfide bridges created favoured the active conformations of the peptide. Here we report the molecular modelling of the conformation of domains involved in receptor activation. Our approach was to create sets of possible conformations for three differently constrained bioactive regions by a random search of conformational space and molecular modelling. The conformations were compared, and those allowed for all derivatives were considered relevant for receptor activation. This approach resulted in one favoured group of conformations characterized by an inverse y-turn followed by a y-turn, denning the conformation of the tripeptide region with a similar sequence in all active analogues. The models may also be used for the design of peptide and non-peptide analogues of CGRP.
Introduction
The calcitonin gene-related peptide (CGRP) is a 37-residue neuropeptide produced by alternative splicing of the calcitonin gene product (Amara et al., 1982) . The effects of CGRP and the related peptide amylin on, for example, the cardiovascular system (Gennari and Fischer, 1985) , bone metabolism (Zaidi etai, 1987) and blood glucose regulation (Sheriffs al., 1992) make it an interesting lead for drug development. Problems associated with the bioavailability and stability of peptides limit the use of CGRP for most applications. Therefore, small molecule analogues of the peptide are needed for medicinal purposes.
Structure-activity studies of CGRP have identified two regions of the hormone which interact independently with the receptor. Short N-terminal fragments activate the receptor (Maggi et al, 1990) , while C-terminai fragments are antagonists of CGRP action (Rovero et al., 1992) . These reports led us to model sets of possible conformations for the N-terminal agonistic fragment CGRP1-20, the C-terminal antagonistic region CGRP30-37 and the whole peptide (Hakala and Vihinen, 1994) . These models facilitated the design of constrained CGRP analogues reduced in size (Hakala et al, 1994) . Some of these have receptor affinities comparable with those of CGRP (Table I) . To our surprise, SH992, an analogue without the N-terminal activating domain, was an agonist-activating adenylate cyclase similar to CGRP. This was concluded to be die result of the disulfide loop designed to constrain the C-© Oxford University Press terminal antagonistic domain. From these studies, we suggested that the N-terminal agonistic region and the C-terminal antagonistic region bind to a similar site in the receptor. The agonistic activity of the N-terminal region could be caused by the constrained conformation induced by the disulfide bridge. If so, then the agonistic activity of SH992 may be explained by the disulfide bridge constraining the conformation of this region to mimic the N-terminal agonistic conformation. Another analogue, SH892, was designed to have a truncated disulfide loop with only three residues inside the loop. This peptide was also an agonist. The studies resulted in three differently constrained disulfide loops which all possess agonistic activity. Because the three disulfide bridges restrict the possible conformations differently, the bioactive conformation may be determined by comparing models of these peptides.
Here we have modelled the constrained regions of these active peptide leads by a random search of conformational space followed by refinement using molecular dynamics. As the sets of possible conformations of each of the peptides were compared, one family of conformations appeared to be favoured for all derivatives. This was characterized by an inverse yturn, followed by a y-turn defining the conformation of the tripeptide region with a similar sequence in all active analogues. Thus, the modelling combined with synthetic results has yielded a picture of a small bioactive region with an ordered structure. In future studies, this model will be used for the design of novel peptide and non-peptide analogues of CGRP.
Materials and methods
Three short sequences representing the bioactive regions of CGRP and analogues thereof were subjected to a random search of conformational space followed by molecular dynamics. The fragments used for the simulations are shown in Figure 1 . PI and P2 are the N-terminal fragments of CGRP and SH892, respectively. P3 is the C-terminal fragment of SH992. In contrast to P3, PI and P2 do not have any measurable affinity for the receptor. P3 binds to the receptor at ^M concentrations (unpublished results, Heino.P). The conformations obtained for each fragment were compared and those allowed for all sequences were considered relevant for biological activity. The flowchart of the modelling approach is displayed in Figure 2 . Details of each step are described below.
Molecular modelling
The modelling was performed using the SYBYL (Tripos Inc., St Louis, MO) program package on a Silicon Graphics Iris Crimson workstation. The TRIPOS forcefield was used for all calculations. The atomic charges were calculated using the Gasteiger HUckel method. A distance-dependent dielectric constant was used to represent the effects of the environment. The simulations were performed for neutral molecules so as to avoid overestimation of the coulombic interactions. All Cterminals were amidated as in the native peptide sequence. The N-terminus was modelled with a neutral amine group. The partial charge of the e-amine of lysine was changed to The N-and C-terminal tripeptide regions essential for receptor interaction are in bold. The receptor affinities (Hakala el al., 1994) were measured as the displacement of lodinated CGRP from rabbit lung preparations at two temperatures. resemble that of a methyl group so as to avoid unnatural hydrogen bonds between the amine and backbone carbonyls.
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Random search
The random search of conformational space was carried out by randomly changing up to three <}>, \y and Xi torsion angles at a time. This was performed on structures lacking the disulfide bridge so as to create unconstrained conformations. The disulfide bridge was formed with those structures which had a distance of < 10 A between the P-carbons of the two cysteines. Only these structures were considered in subsequent work. Each of the structures was minimized after the formation of the disulfide bridge. Sets of 50 structures with a disulfide bridge were created for each fragment.
Molecular dynamics
Each of the structures was refined by applying molecular dynamics. The simulations were for 100 ps at 300 K with a 1 fs time step. The trajectories were saved at 100 fs intervals. The last structure of each trajectory was thoroughly minimized using up to 3000 steps of the Powell algorithm, giving an r.m.s. energy derivative of <0.001 kcal mol"'A~'. Structures within 10 kcal mol" 1 of each fragment were considered for further analysis. 
Division of conformations into families
The structures obtained by the minimization of molecular dynamics endpoints were sorted into families. This was performed by computing the r.m.s. difference between the backbone atoms of each structure. In the case of the more constrained structure P2, two structures with an r.m.s. difference of < 1.5 A were considered similar. In the cases of PI and P3, a less stringent criterion of 2.0 A was applied. Every group of two or more similar structures was considered a family.
Comparison of families
The similarity of families was determined by calculating an r.m.s. difference between the atoms marked with an asterisk in Figure 1 . This tripeptide region was chosen for analysis because it is similar in all three fragments studied. A lowenergy representative of each family was chosen for analysis.
It was compared with all other representatives of other families by superimposing the marked atoms. Pairs with an r.m.s. difference of <0.4 A were considered similar.
Results
Molecular modelling
The random search step was performed for fragments lacking the disulfide bridge. This was carried out to allow for scanning of the conformational space. The disulfide bridges were then formed with those structures having a distance of <10 A between the pVcarbons of the cysteines. In this way, 50 starting conformations were formed for each fragment. Some 139, 120 and 112 unconstrained structures of PI, P2 and P3, respectively, had to be produced so as to obtain 50 structures of each fragment which met the 10 A criterion. Each of the 50 conformations was subjected to a refinement by molecular dynamics followed by minimization. Only structures within 10 kcal mol" 1 were considered for further analysis because these were thought to represent the favoured conformations of the fragments. This screening resulted in 18, 26 and 20 conformations of PI, P2 and P3, respectively.
Division of conformations into families
The low-energy conformations obtained for each fragment were divided into families according to the r.m.s. differences between superimposed backbone atoms (Table II) . The criteria used (1.5 A for P2 and 2.0 A for PI and P3) resulted in five families for PI, six for P2 and four for P3. In addition, there were some conformations that did not fall into any of the families thus obtained.
Comparison of the families
As low-energy members of each family were compared, by superimposing the regions corresponding to Thr-Ala-Thr of PI, one group of conformations shared by all of the fragments was found (Table IH) . This group included the representatives of families I of PI, V of P2 and I of P3. The similar conformations were characterized by an inverse y-turn followed by a y-tum constraining the conformation of the tripeptide region.
The alignment of the tripeptide region of the three different fragments is shown as a stereo drawing in Figure 3 . Discussion Structure-activity relationship studies on CGRP have shown that this peptide has two distinct regions which interact independently with the CGRP receptor (Watanabe et al, 1989) . According to studies on fragments of the peptide, the Nterminal fragments are agonists at the receptor, causing the same physiological responses as the intact peptide (Maggi et al., 1990) , whereas the C-terminal fragments are antagonists of CGRP action (Rovero et al, 1992) . This is analogous to several other peptide hormones like calcitonin (Yamamoto et al., 1981) , the parathyroid hormone 1-34 (Nussbaum et al., 1980; Segre et al, 1985) and the growth hormone-releasing hormone 1-29 (Ling et al, 1984) .
In the case of CGRP and calcitonin, the N-terminal agonistic domain is constrained by a disulfide bridge. In our previous studies on CGRP analogues (Hakala et al, 1994) , the Nterminal loop region responsible for receptor activation was removed. Instead, a cysteine bridge was designed for the Cterminal antagonistic region. This resulted in an analogue, SH992, with rather high affinity for the receptor. Surprisingly, this peptide proved to be an agonist in the adenylate cyclase activation assay. Another peptide, SH892, was designed to contain a truncated and thus more constrained N-terminal disulfide loop. This peptide was also shown to be an agonist with an affinity similar to that of the natural CGRP.
Comparison of the three agonists, CGRP, SH892 and SH992, revealed a similar tripeptide region in both the N-and Cterminal domains (Table I) . This consists of a valine or threonine as the first residue, a glycine at the C-terminal end or an alanine in the N-terminal domain as the second residue, and a serine or threonine as the third residue. The residues preceding and following this tripeptide region are not considered to interact specifically with the receptor because they vary in the different sequences. There is only one residue preceding this tripeptide region in the N-terminal region of SH892 (P2). Even this residue is not conserved in the different analogues because it may be an asparagine or a cysteine. There is also variation in the sequence following the tripeptide region as the C-and N-terminal fragments are compared.
The disulfide bridges constraining the conformation of the putative bioactive tripeptide region are important for the biological activity because the antagonistic C-terminal regions are converted to an agonist by introducing two cysteines into 'the sequence (Hakala et al, 1994) . We assume that the bridges constrain the tripeptide regions into similar conformations in the three different sequences. Thus, the three different sequences provide a possibility of modelling the bioactive conformation of the peptide.
Fragments of each of the three peptides were used for molecular modelling because we were interested in the small structural units defined by short-range interactions. Such ordered structures have been proposed to be present in otherwise disordered structures (Kikuchi, 1992) . They may be responsible for the biological activity of peptides because ordered structures are more likely to be recognized by receptors than random conformations. We also believe that while only a small part of the peptide interacts with the receptor, a larger peptide is needed to maintain the appropriate conformation of the bioactive region. Therefore, we assume that finding the bioactive conformation of a small peptide may lead to the development of nonpeptide analogues in which the compact scaffold maintains the appropriate 3-D arrangement of functional groups interacting with the receptor. The approach using a nonpeptide scaffold has been used successfully in the case of somatostatin, in which (J-D-glucose was used to maintain the spatial arrangement of mimics of peptide side chains (Hirschmann et al., 1992) .
In the case of SH992 with the C-terminal disulfide bridge, the terminal octapeptide (P3) was a natural choice for modelling because it binds to the receptor with (i.M affinity (unpublished results, Heino.P), thus independently forming the bioactive conformation. This is also the case with the corresponding unconstrained C-terminal octapeptide CGRP30-37 modelled previously (Hakala and Vihinen, 1994) . In the case of the Nterminal region, the choice is more difficult because the shortest active analogue reported is CGRP1-12. This is still quite a long peptide, possessing the unconstrained pentapeptide tail. We have assumed that the limiting of the modelling to the disulfide-bridged loop region, with only one residue on both sides outside the loop considered, would be sufficient This is because our main aim was to compare the possible conformations of the region inside the disulfide loop. Of course, the pentapeptide tail may affect the conformation of the loop region because it may favour some of the conformations with specific interactions. Such long-range interactions would be highly speculative because the simulations in vacuo (i) do not take into account the specific interactions with the environment, consisting of the receptor, a lipid bilayer and an aqueous phase, and (ii) overemphasize the intramolecular long-range interactions.
Our approach to the modelling of the peptide analogues was to create sets of possible conformations. The approach was based on our knowledge that peptides have several conformations which are favoured in different environments. This has been shown, for example, with studies on the structure of cyclosporin, a cyclic undecylpeptide. The structure of this peptide has been determined by X-ray crystallographic studies on crystals and by NMR work on chloroform solutions and peptide bound to the receptor, cyclophilin. The studies have shown that, although the structures of the crystalline form and the structure found in chloroform are quite similar, the receptorbound structure is completely different (Fesik et al, 1991; Weber et al, 1991) .
As expected, the modelling approach resulted in several families of favoured conformations for each fragment. One family was found to be shared by all fragments when the tripeptide regions, suggested to be essential for receptor activation, were compared. This structure is constrained, in addition to the disulfide bridge, by two characteristic hydrogen bonds which form an inverse and classic y-turn. It is not expected that these hydrogen bonds could be observed spectroscopically because they represent only one of the possible conformations and may only be present in the receptorbound state. However, they may be verified experimentally by designing peptide analogues in which specific constraints are designed to mimic the turns. This kind of approach has been used by Sato et al. (1992) in the case of bradykinin.
The models may also be used in the search for drugs as a starting point for database searches. It seems obvious that the methyl of the residue corresponding to Thr4 and the hydroxyl of the residue corresponding to Thr6 of CGRP (P1) form at least one part of the pharmacophore because these are conserved in all the sequences. They are also conserved in the agonistic part of the related peptides amylin and calcitonin. The distances between the a-carbons and ap" vectors of these two residues are well defined in the modelled bioactive conformations and they would be good targets for the search.
There still remains uncertainties in the models. For example, the Xi angles rotate freely, making it impossible to determine the distance between the hydroxyl and methyl groups interacting with the receptor. The model could be refined by designing new constrained analogues to mimic the modelled conformations with Xi angles constrained. The modelling of the peptide-receptor interaction by docking the modelled conformations into the receptor cavity would also provide insight into the probable Xi angles and the importance of the residues not considered now.
